AIM2 and neoplasm: Notably, the integration of AIM2-targeted therapy with existing immunotherapeutic modalities, including anti-PD-1/PD-L1 inhibitors, chimeric antigen receptor T (CAR-T) cell therapy, and pharmacological agents such as osimertinib, holds potential for enhancing therapeutic outcomes, particularly in tumor types characterized by comparatively weak immune responses.